Does the media prefer RMTI or NEPH?

In the previous week, Nephros had 4 more articles in the media than Rockwell Medical. MarketBeat recorded 5 mentions for Nephros and 1 mentions for Rockwell Medical. Nephros' average media sentiment score of 0.72 beat Rockwell Medical's score of -0.50 indicating that Nephros is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Rockwell Medical 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Negative Nephros 1 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts rate NEPH or EVTV?

Nephros currently has a consensus price target of $4.00, indicating a potential downside of 4.99%. Given Nephros' stronger consensus rating and higher probable upside, research analysts clearly believe Nephros is more favorable than Envirotech Vehicles. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Nephros 0 Sell rating(s) 3 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00 Envirotech Vehicles 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Is NEPH or EVTV more profitable?

Nephros has a net margin of 8.38% compared to Envirotech Vehicles' net margin of -382.71%. Nephros' return on equity of 11.03% beat Envirotech Vehicles' return on equity. Company Net Margins Return on Equity Return on Assets Nephros 8.38% 11.03% 8.38% Envirotech Vehicles -382.71% -1,284.22% -181.53%

Does the media refer more to NEPH or EVTV?

In the previous week, Nephros had 4 more articles in the media than Envirotech Vehicles. MarketBeat recorded 5 mentions for Nephros and 1 mentions for Envirotech Vehicles. Nephros' average media sentiment score of 0.72 beat Envirotech Vehicles' score of 0.00 indicating that Nephros is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Nephros 1 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Envirotech Vehicles 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts recommend RVP or NEPH?

Nephros has a consensus price target of $4.00, indicating a potential downside of 4.99%. Given Nephros' stronger consensus rating and higher possible upside, analysts plainly believe Nephros is more favorable than Retractable Technologies. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Retractable Technologies 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Nephros 0 Sell rating(s) 3 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00

Which has stronger earnings & valuation, BMRA or NEPH?

Nephros has higher revenue and earnings than Biomerica. Biomerica is trading at a lower price-to-earnings ratio than Nephros, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Biomerica $4.33M 1.17 -$4.97M -$0.89 N/A Nephros $18.79M 2.43 $1.19M $0.07 60.14

Is BMRA or NEPH more profitable?

Nephros has a net margin of 8.38% compared to Biomerica's net margin of -96.49%. Nephros' return on equity of 11.03% beat Biomerica's return on equity. Company Net Margins Return on Equity Return on Assets Biomerica -96.49% -98.14% -70.42% Nephros 8.38% 11.03% 8.38%

Do analysts rate LUCY or NEPH?

Nephros has a consensus target price of $4.00, indicating a potential downside of 4.99%. Given Nephros' stronger consensus rating and higher probable upside, analysts plainly believe Nephros is more favorable than Innovative Eyewear. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Innovative Eyewear 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.50 Nephros 0 Sell rating(s) 3 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00

Does the media prefer LUCY or NEPH?

In the previous week, Nephros had 4 more articles in the media than Innovative Eyewear. MarketBeat recorded 5 mentions for Nephros and 1 mentions for Innovative Eyewear. Nephros' average media sentiment score of 0.72 beat Innovative Eyewear's score of 0.00 indicating that Nephros is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Innovative Eyewear 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Nephros 1 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Nephros (NEPH) Competitors

$4.21 +0.62 (+17.27%)

Closing price 08/7/2026 04:00 PM Eastern

Extended Trading

$4.18 -0.03 (-0.59%)

As of 08/7/2026 07:56 PM Eastern

Compare

NEPH vs. RMTI, EVTV, RVP, BMRA, and LUCY

Should you buy Nephros stock or one of its competitors? MarketBeat compares Nephros with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Nephros include Rockwell Medical (RMTI), Envirotech Vehicles (EVTV), Retractable Technologies (RVP), Biomerica (BMRA), and Innovative Eyewear (LUCY). These companies are all part of the "healthcare supplies" industry.

How does Nephros compare to Rockwell Medical?

Rockwell Medical (NASDAQ:RMTI) and Nephros (NASDAQ:NEPH) are both small-cap healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their risk, media sentiment, valuation, earnings, dividends, institutional ownership, profitability and analyst recommendations.

Nephros has lower revenue, but higher earnings than Rockwell Medical. Rockwell Medical is trading at a lower price-to-earnings ratio than Nephros, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Rockwell Medical	$69.26M	0.41	-$5.31M	-$1.50	N/A
Nephros	$18.79M	2.43	$1.19M	$0.07	60.14

Rockwell Medical has a beta of 1.6, indicating that its stock price is 60% more volatile than the broader market. Comparatively, Nephros has a beta of 1.51, indicating that its stock price is 51% more volatile than the broader market.

Nephros has a net margin of 8.38% compared to Rockwell Medical's net margin of -7.98%. Nephros' return on equity of 11.03% beat Rockwell Medical's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Rockwell Medical	-7.98%	-15.41%	-9.62%
Nephros	8.38%	11.03%	8.38%

Rockwell Medical presently has a consensus target price of $20.00, indicating a potential upside of 180.11%. Nephros has a consensus target price of $4.00, indicating a potential downside of 4.99%. Given Rockwell Medical's higher possible upside, research analysts clearly believe Rockwell Medical is more favorable than Nephros.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Rockwell Medical	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Nephros	0 Sell rating(s)	3 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00

In the previous week, Nephros had 4 more articles in the media than Rockwell Medical. MarketBeat recorded 5 mentions for Nephros and 1 mentions for Rockwell Medical. Nephros' average media sentiment score of 0.72 beat Rockwell Medical's score of -0.50 indicating that Nephros is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Rockwell Medical	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Negative
Nephros	1 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

23.3% of Rockwell Medical shares are held by institutional investors. Comparatively, 41.1% of Nephros shares are held by institutional investors. 4.6% of Rockwell Medical shares are held by company insiders. Comparatively, 6.7% of Nephros shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Summary

Nephros beats Rockwell Medical on 11 of the 15 factors compared between the two stocks.

How does Nephros compare to Envirotech Vehicles?

Nephros (NASDAQ:NEPH) and Envirotech Vehicles (NASDAQ:EVTV) are both small-cap healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their profitability, analyst recommendations, risk, media sentiment, institutional ownership, dividends, valuation and earnings.

Nephros has higher revenue and earnings than Envirotech Vehicles. Envirotech Vehicles is trading at a lower price-to-earnings ratio than Nephros, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Nephros	$18.79M	2.43	$1.19M	$0.07	60.14
Envirotech Vehicles	$5.94M	4.24	-$39.13M	-$6.45	N/A

Nephros has a net margin of 8.38% compared to Envirotech Vehicles' net margin of -382.71%. Nephros' return on equity of 11.03% beat Envirotech Vehicles' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Nephros	8.38%	11.03%	8.38%
Envirotech Vehicles	-382.71%	-1,284.22%	-181.53%

In the previous week, Nephros had 4 more articles in the media than Envirotech Vehicles. MarketBeat recorded 5 mentions for Nephros and 1 mentions for Envirotech Vehicles. Nephros' average media sentiment score of 0.72 beat Envirotech Vehicles' score of 0.00 indicating that Nephros is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Nephros	1 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Envirotech Vehicles	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Nephros currently has a consensus price target of $4.00, indicating a potential downside of 4.99%. Given Nephros' stronger consensus rating and higher probable upside, research analysts clearly believe Nephros is more favorable than Envirotech Vehicles.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Nephros	0 Sell rating(s)	3 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00
Envirotech Vehicles	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Nephros has a beta of 1.51, meaning that its share price is 51% more volatile than the broader market. Comparatively, Envirotech Vehicles has a beta of 0.85, meaning that its share price is 15% less volatile than the broader market.

41.1% of Nephros shares are held by institutional investors. Comparatively, 5.7% of Envirotech Vehicles shares are held by institutional investors. 6.7% of Nephros shares are held by company insiders. Comparatively, 17.8% of Envirotech Vehicles shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Summary

Nephros beats Envirotech Vehicles on 13 of the 15 factors compared between the two stocks.

How does Nephros compare to Retractable Technologies?

Retractable Technologies (NYSE:RVP) and Nephros (NASDAQ:NEPH) are both small-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, valuation, analyst recommendations, media sentiment, institutional ownership, earnings, dividends and profitability.

Nephros has a net margin of 8.38% compared to Retractable Technologies' net margin of -41.11%. Nephros' return on equity of 11.03% beat Retractable Technologies' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Retractable Technologies	-41.11%	-17.15%	-9.33%
Nephros	8.38%	11.03%	8.38%

In the previous week, Nephros had 5 more articles in the media than Retractable Technologies. MarketBeat recorded 5 mentions for Nephros and 0 mentions for Retractable Technologies. Nephros' average media sentiment score of 0.72 beat Retractable Technologies' score of 0.00 indicating that Nephros is being referred to more favorably in the news media.

Company	Overall Sentiment
Retractable Technologies	Neutral
Nephros	Positive

7.6% of Retractable Technologies shares are held by institutional investors. Comparatively, 41.1% of Nephros shares are held by institutional investors. 59.5% of Retractable Technologies shares are held by company insiders. Comparatively, 6.7% of Nephros shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Retractable Technologies has a beta of 1.22, indicating that its stock price is 22% more volatile than the broader market. Comparatively, Nephros has a beta of 1.51, indicating that its stock price is 51% more volatile than the broader market.

Nephros has a consensus price target of $4.00, indicating a potential downside of 4.99%. Given Nephros' stronger consensus rating and higher possible upside, analysts plainly believe Nephros is more favorable than Retractable Technologies.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Retractable Technologies	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Nephros	0 Sell rating(s)	3 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00

Nephros has lower revenue, but higher earnings than Retractable Technologies. Retractable Technologies is trading at a lower price-to-earnings ratio than Nephros, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Retractable Technologies	$37.15M	0.54	-$7.01M	-$0.21	N/A
Nephros	$18.79M	2.43	$1.19M	$0.07	60.14

Summary

Nephros beats Retractable Technologies on 13 of the 15 factors compared between the two stocks.

How does Nephros compare to Biomerica?

Biomerica (NASDAQ:BMRA) and Nephros (NASDAQ:NEPH) are both small-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their dividends, profitability, valuation, media sentiment, analyst recommendations, earnings, risk and institutional ownership.

22.3% of Biomerica shares are owned by institutional investors. Comparatively, 41.1% of Nephros shares are owned by institutional investors. 18.0% of Biomerica shares are owned by company insiders. Comparatively, 6.7% of Nephros shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Nephros has higher revenue and earnings than Biomerica. Biomerica is trading at a lower price-to-earnings ratio than Nephros, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Biomerica	$4.33M	1.17	-$4.97M	-$0.89	N/A
Nephros	$18.79M	2.43	$1.19M	$0.07	60.14

Biomerica currently has a consensus target price of $9.00, suggesting a potential upside of 447.11%. Nephros has a consensus target price of $4.00, suggesting a potential downside of 4.99%. Given Biomerica's higher possible upside, equities research analysts plainly believe Biomerica is more favorable than Nephros.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Biomerica	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Nephros	0 Sell rating(s)	3 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00

In the previous week, Nephros had 5 more articles in the media than Biomerica. MarketBeat recorded 5 mentions for Nephros and 0 mentions for Biomerica. Nephros' average media sentiment score of 0.72 beat Biomerica's score of 0.00 indicating that Nephros is being referred to more favorably in the news media.

Company	Overall Sentiment
Biomerica	Neutral
Nephros	Positive

Nephros has a net margin of 8.38% compared to Biomerica's net margin of -96.49%. Nephros' return on equity of 11.03% beat Biomerica's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Biomerica	-96.49%	-98.14%	-70.42%
Nephros	8.38%	11.03%	8.38%

Biomerica has a beta of 0.35, indicating that its share price is 65% less volatile than the broader market. Comparatively, Nephros has a beta of 1.51, indicating that its share price is 51% more volatile than the broader market.

Summary

Nephros beats Biomerica on 13 of the 15 factors compared between the two stocks.

How does Nephros compare to Innovative Eyewear?

Innovative Eyewear (NASDAQ:LUCY) and Nephros (NASDAQ:NEPH) are both small-cap healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their analyst recommendations, profitability, dividends, valuation, risk, earnings, media sentiment and institutional ownership.

Nephros has a net margin of 8.38% compared to Innovative Eyewear's net margin of -272.42%. Nephros' return on equity of 11.03% beat Innovative Eyewear's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Innovative Eyewear	-272.42%	-83.37%	-76.02%
Nephros	8.38%	11.03%	8.38%

Innovative Eyewear has a beta of 2.72, suggesting that its share price is 172% more volatile than the broader market. Comparatively, Nephros has a beta of 1.51, suggesting that its share price is 51% more volatile than the broader market.

Nephros has a consensus target price of $4.00, indicating a potential downside of 4.99%. Given Nephros' stronger consensus rating and higher probable upside, analysts plainly believe Nephros is more favorable than Innovative Eyewear.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Innovative Eyewear	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50
Nephros	0 Sell rating(s)	3 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00

Nephros has higher revenue and earnings than Innovative Eyewear. Innovative Eyewear is trading at a lower price-to-earnings ratio than Nephros, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Innovative Eyewear	$2.66M	1.73	-$7.59M	-$1.69	N/A
Nephros	$18.79M	2.43	$1.19M	$0.07	60.14

1.0% of Innovative Eyewear shares are held by institutional investors. Comparatively, 41.1% of Nephros shares are held by institutional investors. 1.7% of Innovative Eyewear shares are held by company insiders. Comparatively, 6.7% of Nephros shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

In the previous week, Nephros had 4 more articles in the media than Innovative Eyewear. MarketBeat recorded 5 mentions for Nephros and 1 mentions for Innovative Eyewear. Nephros' average media sentiment score of 0.72 beat Innovative Eyewear's score of 0.00 indicating that Nephros is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Innovative Eyewear	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Nephros	1 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Nephros beats Innovative Eyewear on 14 of the 15 factors compared between the two stocks.

Get Nephros News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding NEPH and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

NEPH vs. The Competition

Export

Metric	Nephros	Healthcare Equipment & Supplies Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$38.97M	$5.75B	$6.94B	$12.87B
Dividend Yield	N/A	1.79%	2.59%	9.91%
P/E Ratio	26.31	24.18	270.55	25.24
Price / Sales	2.43	40.08	598.33	98.58
Price / Cash	28.62	32.81	71.46	49.72
Price / Book	4.39	5.70	13.26	6.22
Net Income	$1.19M	$148.58M	$3.45B	$342.81M
7 Day Performance	24.19%	4.68%	4.66%	4.42%
1 Month Performance	27.19%	1.35%	-0.78%	-0.27%
1 Year Performance	7.95%	9.53%	77.76%	22.59%

Nephros Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
NEPH Nephros	2.9976 of 5 stars	$4.21 +17.3%	$4.00 -5.0%	+45.7%	$38.97M	$18.79M	26.31	30	News Coverage Earnings Report Gap Up High Trading Volume
RMTI Rockwell Medical	3.1105 of 5 stars	$7.15 -5.5%	$20.00 +179.7%	-27.1%	$28.39M	$69.26M	N/A	300	News Coverage Upcoming Earnings Analyst Upgrade
EVTV Envirotech Vehicles	0.0774 of 5 stars	$1.95 +0.3%	N/A	+8.2%	$25.16M	$5.94M	N/A	10	News Coverage
RVP Retractable Technologies	N/A	$0.67 +0.7%	N/A	-10.7%	$20.20M	$37.15M	N/A	240
BMRA Biomerica	1.8929 of 5 stars	$1.60 +4.6%	$9.00 +462.5%	-47.1%	$4.94M	$4.33M	N/A	60

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:NEPH) was last updated on 8/8/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Nephros (NEPH) Competitors

NEPH vs. RMTI, EVTV, RVP, BMRA, and LUCY

How does Nephros compare to Rockwell Medical?

Summary

How does Nephros compare to Envirotech Vehicles?

Summary

How does Nephros compare to Retractable Technologies?

Summary

How does Nephros compare to Biomerica?

Summary

How does Nephros compare to Innovative Eyewear?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

NEPH vs. The Competition

Nephros Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Nephros (NEPH) Competitors

NEPH vs. RMTI, EVTV, RVP, BMRA, and LUCY

How does Nephros compare to Rockwell Medical?

Which has higher earnings and valuation, RMTI or NEPH?

Which has more risk & volatility, RMTI or NEPH?

Is RMTI or NEPH more profitable?

Do analysts rate RMTI or NEPH?

Does the media prefer RMTI or NEPH?

Do insiders and institutionals hold more shares of RMTI or NEPH?

Summary

How does Nephros compare to Envirotech Vehicles?

Which has stronger earnings and valuation, NEPH or EVTV?

Is NEPH or EVTV more profitable?

Does the media refer more to NEPH or EVTV?

Do analysts rate NEPH or EVTV?

Which has more volatility and risk, NEPH or EVTV?

Do institutionals & insiders believe in NEPH or EVTV?

Summary

How does Nephros compare to Retractable Technologies?

Is RVP or NEPH more profitable?

Does the media prefer RVP or NEPH?

Do insiders and institutionals believe in RVP or NEPH?

Which has more risk and volatility, RVP or NEPH?

Do analysts recommend RVP or NEPH?

Which has higher valuation & earnings, RVP or NEPH?

Summary

How does Nephros compare to Biomerica?

Do insiders & institutionals hold more shares of BMRA or NEPH?

Which has stronger earnings & valuation, BMRA or NEPH?

Do analysts recommend BMRA or NEPH?

Does the media prefer BMRA or NEPH?

Is BMRA or NEPH more profitable?

Which has more risk & volatility, BMRA or NEPH?

Summary

How does Nephros compare to Innovative Eyewear?

Is LUCY or NEPH more profitable?

Which has more volatility and risk, LUCY or NEPH?

Do analysts rate LUCY or NEPH?

Which has preferable earnings & valuation, LUCY or NEPH?

Do insiders and institutionals believe in LUCY or NEPH?

Does the media prefer LUCY or NEPH?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

NEPH vs. The Competition

Nephros Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools